Clinical stage, pharmaceutical company, with proprietary AI platforms, Exscientia announced completion of USD 225 million series D funding round, along with availability of additional USD 300 million equity commitment that can be drawn at the Company’s discretion. The round of funding was led by SoftBank Vision Fund 2 and was also joined by Novo Holdings and funds, Blackrock, Mubadala Investment Company, Farallon Capital, GT Healthcare capital, Bristol-Myers Squibb and other investors.
The funds will be used by Exscientia to accelerate the pace of development of nearly 20 active candidates in pipeline to potentially move them further into clinical testing phases. Presently, the pipeline holds 2 assets in clinical stage, including an immune-oncology focused asset developed in partnership with Evotec. The pipeline candidates are focused on various therapeutic areas including oncology, immunity, rare diseases, respiratory, psychiatry, COVID-19 etc. To accelerate the development, Exscientia has also forged multiple partnerships with leading large pharma companies such as BMS, Sanofi, Bayer, Rally and another with the Gates foundation.
Founded in 2012, Oxford based company leveraging its AI platform for target identification, drug designing and patient selection. Its two platform offerings include CentaurAI and ExperimentAI. While CentaurAI enable sin optimized target selection, ExperimentAI provides further intervention in experiments along with feedback mechanism for refined connection of prediction and hypothesis with the study and machine learning modules backing up development of candidates at diverse levels of experimentations.
Exscientia is the first company to have taken small molecule drug candidates from early, AI driven drug discovery to clinical trials. It has gained interest of multiple investors over time and the financial backing will potentially thrust its patient centric, precision drug development pace and is one of the leading players gaining traction in the segment of AI based players accelerating drug discovery.